Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for treating angiogenic diseases using extracellular matrix membrane of cartilage-derived cell, and transplant material for cornea or conjunctiva

A technology of chondrocytes and extracellular matrix, applied in corneal or conjunctival grafts, and in the field of compositions for treating corneal angiogenesis-related diseases, can solve problems such as high production costs and production limitations, and achieve prevention and inhibition of angiogenesis , Inhibition of vascularization and vascular invasion

Inactive Publication Date: 2015-08-12
AJOU UNIV IND ACADEMIC COOP FOUND
View PDF11 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, there is also the problem of high production costs associated with the safety of amnion, and mass production is limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating angiogenic diseases using extracellular matrix membrane of cartilage-derived cell, and transplant material for cornea or conjunctiva
  • Composition for treating angiogenic diseases using extracellular matrix membrane of cartilage-derived cell, and transplant material for cornea or conjunctiva
  • Composition for treating angiogenic diseases using extracellular matrix membrane of cartilage-derived cell, and transplant material for cornea or conjunctiva

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1: Preparation of CD-ECM and amniotic membrane

[0065] Chondrocyte-derived extracellular matrix membrane (hereinafter referred to as "CD-ECM") used as a composition for treating corneal angiogenesis-related diseases and as a base material for corneal or conjunctival grafts according to exemplary embodiments of the present invention is a membranous scaffold prepared as follows.

[0066]CD-ECM is a membranous extracellular matrix membrane prepared by collecting and culturing chondrocytes derived from knee cartilage in sterile pigs. The CD-ECM used here is a material currently clinically used in orthopedics for the purpose of cartilage regeneration only. The extracellular matrix secreted during monolayer culture of chondrocytes isolated from patella cartilage in sterile pigs is dried in the form of membranes or sheets, decellularized using enzymes such as DNase I, and then washed with PBS buffer rinsing. The extracellular matrix thus obtained is a biofilm with ...

Embodiment 2

[0070] Example 2: Cell Culture

[0071] Vascular endothelial cells and chondrocytes each attached to the CD-ECM of Example 1 and the control group (ie, amniotic membrane) to be used in the in vitro test and the in vivo test were cultured in advance as follows.

[0072] First, human umbilical vein endothelial cells (HUVECs) as vascular endothelial cells were cultured in endothelial cell-containing medium supplemented with growth factors (Promega, Wisconsin, USA), 10 μg / ml bFGF and 2% FBS, and placed in Inoculate 1×10 per plate on the culture plate 6 cells, then, at a temperature of 37 °C in 5% CO 2 cultivated in an incubator. Two days after seeding HUVECs, cells not attached to the culture plate were removed, while cells attached to the culture plate were continued in culture. 14 days after inoculation of human umbilical vein vascular endothelial cells (HUVEC), the human umbilical vein vascular endothelial cells attached to the culture plate were removed by using trypsin, an...

Embodiment 3

[0074] Example 3: Cell Attachment Analysis of Chondrocytes and Vascular Endothelial Cells (eg, HUVECs)

[0075] Depending on the materials of the CD-ECM of Example 1 and the control group (ie, amnion), the difference in attachment rate between chondrocytes and vascular endothelial cells (eg, HUVEC) was confirmed as follows.

[0076] First, CD-ECM (5 mm in diameter) and amnion were each independently attached to a 24-well dish, dried, and sterilized using ionized gas. Then, the 24-well dishes on which CD-ECM and amnion were independently coated were inoculated with 1×10 3 chondrocytes and 1×10 3 vascular endothelial cells. For fluorescent staining of cells, 40 μl of calcein AM (2 μg / ml) (Invitrogen, Wisconsin, USA) was added thereto, and then, at a temperature of 37° C. in 5% CO 2 cultured in an incubator for 24 hours. Here, a medium supplemented with 10% FBS and DMEM was used for culturing chondrocytes, while a medium supplemented with 10 μg / ml bFGF, 2% FBS, and endothelia...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a novel composition for treating angiogenic diseases using an extracellular matrix membrane of a cartilage-derived cell having a membrane or film form, which is excreted from cartilage cells that are cultured when the cartilage cells isolated from the cartilage of an animal is monolayer-cultured, and a transplant material for the cornea or the conjunctiva. The composition for treating the angiogenic diseases and the transplant material for the cornea or the conjunctiva, according to the present invention, suppresses endothelial cells from attaching or proliferating and impedes the movement of endothelial cells, thereby suppressing vascular endothelial growth and vascular penetration and thus ultimately suppressing angiogenesis. [Reference numerals] (AA) Matrigel; (BB) Matrigel / CD-ECM powder; (CC) Matrigel / Amnion powder

Description

technical field [0001] The present invention relates to a composition for treating angiogenesis-related diseases using a chondrocyte-derived extracellular matrix membrane, and a corneal or conjunctival graft. In particular, the present invention relates to compositions for the treatment of angiogenesis-related diseases such as pterygium based on the anti-angiogenic activity of chondrocyte-derived extracellular matrix membranes, and corneal or conjunctival grafts. [0002] In particular, the present invention relates to compositions for the treatment of corneal angiogenesis-related diseases such as pterygium, and corneal or conjunctival grafts based on the anti-angiogenic activity of scaffolds using cartilage obtained from animals Chondrocyte-derived extracellular matrices of tissues and / or chondrocytes are produced in membrane form. [0003] In addition, the present invention relates to novel uses related to chondrocyte-derived extracellular matrix membranes based on anti-ang...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/32A61K35/12A61P35/00A61P27/02
CPCA61K35/32A61P9/00
Inventor 闵炳显朴索拉崔秉显梁在郁尹正镐
Owner AJOU UNIV IND ACADEMIC COOP FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products